Stiris Research Inc. collaborates with US biotech to conduct preliminary feasibility in Non-Hodgkin’s Lymphoma

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it is collaborating with a US biotech company to perform preliminary feasibility in North America for their Phase I/II Non-Hodgkin’s Lymphoma trial.

“We are excited to be able to work with this company on preliminary feasibility to assist them in determining the right sites and appropriate landscape to conduct their trial. Having the ability to work with a sponsor to do preliminary feasibility allows us to truly be involved in the strategic aspects early in the process to ensure its design and conduct are maximized and ultimately meeting crucial milestones and timelines,” Lisa Discepola, Managing Director, Clinical Operations.

Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. The American Cancer Society’s estimates about 70,000 people will be diagnosed with NHL annually, this is both in adults and pediatrics (Statistics adapted from the American Cancer Society’s (ACS) publications).